New hope for advanced cancers? first human trial of TH9619 begins

NCT ID NCT07151040

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called TH9619 in about 43 adults with advanced solid tumors, including colorectal, head and neck, lung, and gastric cancers. The main goal is to check the drug's safety and find the right dose. Participants must have already tried at least one standard chemotherapy. The study is open-label, meaning everyone knows they are getting the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TH9619 (an experimental drug)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is a very early, first-in-human study with only 43 participants. The drug may not be safe or effective, and side effects are unknown. Many early-stage cancer drugs fail to advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hospital Universitario Fundacion Jimenez Diaz

    RECRUITING

    Madrid, Spain

  • Institut Gustave Roussy

    RECRUITING

    Villejuif, France

  • Newcastle University

    RECRUITING

    Newcastle upon Tyne, United Kingdom

  • Vall D Hebron Institute Of Oncology

    RECRUITING

    Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.